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ABSTRACT
Cancer-related investigations have long been in
the limelight of biomedical research. Years of
effort from scientists and doctors worldwide have
generated large amounts of data at the genome,
transcriptome, proteome and even metabolome
level, and DNA and RNA cancer signature databases
have been established. Here we present a data-
base of differentially expressed proteins in human
cancers (dbDEPC), with the goal of collecting
curated cancer proteomics data, providing a
resource for information on protein-level expression
changes, and exploring protein profile differences
among different cancers. dbDEPC currently
contains 1803 proteins differentially expressed in
15 cancers, curated from 65 mass spectrometry
(MS) experiments in peer-reviewed publications.
In addition to MS experiments, low-throughput
experiment data from the same literatures and
cancer-associated genes from external databases
were also integrated to provide some validation
information. Furthermore, dbDEPC associates dif-
ferential proteins with important structural varia-
tions in the human genome, such as copy number
variations or single nucleotide polymorphisms,
which might be helpful for explaining changes in
protein expression at the DNA level. Data in
dbDEPC can be queried by protein identifier,
description or sequence; the retrieved protein
entry provides the differential expression pattern
seen in cancers, along with detailed annotations.
dbDEPC is expected to be a reference database
for cancer signatures at the protein level. This
database is provided at http://dbdepc.biosino
.org/index/.
INTRODUCTION
Cancer is a class of diseases in which abnormal cells
divide without control and are able to invade other
tissues (1). These diseases are a leading cause of death
worldwide, accounting for seven million deaths in 2008
(based on ‘World Cancer Report 2008’, from the WHO).
A promising approach to cancer detection and treat-
ment is based on reliable biomarker discovery, which
assesses molecular changes between cancerous and
normal tissue. For many years, scientists have been
searching for biomarkers to aid in cancer diagnosis,
prognosis and therapy (2). Knowledge of cancer
biomarkers has increased greatly with improvements
in screening methods, from conventional experiments
(e.g. gel electrophoresis and immunohistochemistry)
to high-throughput technologies (e.g. microarray, mass
spectrometry [MS] and sequencing).
In recent decades, several cancer-related database
systems have been developed to associate human genes
with cancers. CGED (3) and ITTACA (4) collect cancer-
related gene expression and clinical data. TAG (http://
www.binfo.ncku.edu.tw/TAG/GeneDoc.php, 519genes)
and TGDBs (http://www.tumor-gene.org/Breast/index
.html, 300genes) provide repositories for cancer-related
genes (e.g. oncogenes, tumor suppressor genes).
COSMIC (5) stores 78933 somatic mutation information
related to human cancers. All these databases focus
on DNA/RNA level changes, such as mutation, single
nucleotide polymorphisms (SNPs) and mRNA expression
change. Most pathophysiologic changes in cancer,
however, are mediated by expression change at the
protein level (6).
In the post-genomic era, proteomics has been developed
to quantify protein expression changes. The primary tech-
nology of quantitative proteomics is stable isotope
labeling combined with liquid chromatography tandem
MS (LC-MS/MS) (7), which has been used successfully
in lung cancer (8–10), breast cancer (11–13), leukemia
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employed iTRAQ-2DLC-MS/MS to identify potential
biomarkers of oral premalignant lesions (OPLs), and the
subsequent immunohistochemistry veriﬁed that the com-
bination of three best-performing biomarkers achieved a
sensitivity of 0.83 and a speciﬁcity of 0.74 in discriminat-
ing OPLs from normal oral tissues (15).
With more and more cancer proteomic research being
performed, a unifying bioinformatic resource is required
to collect and analyze the resulting data. Thus we have
developed a manually curated database of diﬀerentially
expressed proteins in human cancers (dbDEPC). This
database integrates results from various MS experiments
to provide protein-level expression changes for 1803
proteins in 15 cancers. Compared with previous cancer-
related databases, dbDEPC is a novel resource, in provid-
ing information on diﬀerentially expressed proteins; thus,
it may become an important repository for candidate
protein biomarkers. Genomic structure variations also
are provided in dbDEPC, to combine information
on cancer-related protein-level and DNA-level changes.
All data can be searched, browsed and downloaded
directly from the website.
DATA COLLECTION
A semi-automatic method was used to curate diﬀerentially
expressed proteins from peer-reviewed MS-related papers,
as follows:
(i) PubMed was automatically searched using MS-
related keywords (mass spectrometry, proteomics,
quantitative) and cancer-related keywords (cancer,
carcinoma), with search results limited to papers
published before April 2009 for the current version
of dbDEPC.
(ii) To control data quality, retrieved papers were
selected by manually checking whether protein iden-
tiﬁcation and diﬀerential expression ﬁltering
were implemented by strict score cutoﬀ or P-value
of a statistical test. After this quality control step,
65 MS experiments in 47 papers were retained for
further data collection (Supplementary Table S1).
Diﬀerentially expressed proteins had 1.5-fold
change in 63% of experiments and P<0.05 in
25% of experiments, conﬁrming high data quality.
Among 65 experiments, 58 experiments were
designed for human cancers, 5 for mouse and 2
for rat. Although dbDEPC focuses on diﬀerentially
expressed proteins in human cancers, proteins in
mouse and rat were kept for future development.
(iii) The 47 original papers retained in step (ii) used
protein ID numbers from various versions of diﬀer-
ent databases. Based on these ID numbers, we
retrieved each primary sequence from the appropri-
ate database and mapped sequences to the uniform
IPI database (16) (human IPI version 3.60, mouse
and rat IPI version 3.56), using the BLASTP
program (17) (the e-value cutoﬀ was set to 10
8,
the BLAST-HSP coverage was >0.95).
(iv) In addition to MS experiments, low-throughput
(LTP) experiments, including western blot,
immunohistochemistry, ELISA and real-time PCR,
often were implemented in original publications
to validate the diﬀerential expression of potential
biomarkers. Such validation information was
imported into dbDEPC.
(v) The PAnnBuilder package (18) was utilized to
acquire general protein annotation information,
such as protein description, gene symbol, Entrez
gene ID, Gene Ontology (19), Pfam domain (20)
and associated pathways (21). Additionally, SNPs
and other genomic variations were downloaded
from the dbSNP (22) and DGV databases (23),
and integrated into dbDEPC.
(vi) To associate dbDEPC with other cancer-related
databases, CGDCP and CGC were integrated into
dbDEPC by Entrez gene ID. [CGDCP is the Cancer
Gene Data Curation Project, which associates genes
and diseases by text mining and manual checking
(http://ncicb.nci.nih.gov/projects/cgdcp); CGC is
the Cancer Gene Census, which collects cancer-
related gene mutations (http://www.sanger.ac
.uk/genetics/CGP/Census/).]
DATABASE CONSTRUCTION
dbDEPC consists of a relational database and a dynamic
web interface, constructed in the Python 2.6 programming
language (http://www.python.org/), conﬁgured on a
RedHat Linux server, and run via a Django web frame-
work (http://www.djangoproject.com/) with an Apache
server (http://www.apache.org/).
DATABASE CONTENT
Currently, dbDEPC contains 1803 diﬀerentially expressed
proteins from 15 cancers: lung adenocarcinoma, gas-
tric cancer, hepatocellular carcinoma (HCC), colorectal
cancer, breast cancer, prostate cancer, esophageal cancer,
cervical cancer, pancreatic carcinoma, ovarian cancer,
leukemia, thyroid cancer, OPLs, uterine cancer and oral
cancer. A few proteins in mouse and rat are included in
dbDEPC, but we focus on 1487 human proteins (1370
human genes) in this paper.
Figure 1A illustrates the number of diﬀerentially
expressed proteins collected for each cancer type. Taking
HCC as an example, 647 proteins are diﬀerentially
expressed, among which 261 proteins are up-regulated
and 323 proteins are down-regulated. Another 63
proteins show conﬂicting expression change (up or
down) in diﬀerent HCC experiments, which might be
due to diﬀerent HCC samples or experimental protocols.
dbDEPC provides more informative and reliable data
than does a single experiment under such circumstances,
showing the advantage of data integration.
We compared the content of dbDEPC with that of two
existing cancer-associated gene databases (CGDCP,
CGC). Most diﬀerentially expressed genes in dbDEPC
are newly identiﬁed, with only 11% of genes shared with
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validated by LTP experiments, only 8% overlap with
external databases (Figure 1B). These results indicate
that dbDEPC will be an important complement to
previous databases.
We also explored whether diﬀerentially expressed genes
in dbDEPC were associated with genomic variations. As
shown in Figure 1C, 99% of dbDEPC genes have known
SNPs (dbSNP database) and 41% of genes have known
structural variations in the human genome (including copy
number variations, inversions and insert-deletions; DGV
database). This rate of DNA-level variation is signiﬁcantly
higher than that seen for general human genes, by Fisher’s
exact test (P<0.0001). This result may oﬀer a starting
point for explaining the mechanism of protein expression
change in cancers.
DATABASE UTILITY
dbDEPC provides two types of searching models on its
search page (Figure 2A). One is text search, supporting
protein IPI identiﬁer, Entrez gene ID or protein descrip-
tion. Another is sequence similarity search by BLASTP.
dbDEPC’s browsing function is implemented via the
browse page (Figure 2B). Users can select one or
multiple cancers to browse diﬀerentially expressed
proteins. Search and browse results list basic information
for protein matches (Figure 2C), such as IPI ID, descrip-
tion, related cancer and expression change (up or down).
More detailed information for each protein can be
accessed by clicking the protein ID link, as shown in
Figure 2D (and detailed in Supplementary Figure S1).
Detailed information contains three sections: summary,
expression and annotation (Supplementary Figure S1).
The summary section summarizes expression changes
seen in diﬀerent cancers, as well as providing protein
description, IDs, molecular weight and isoelectric point.
The expression section plots a heatmap to visualize the
expression change of proteins in multiple cancers, and
provides information about all MS experiments that
have identiﬁed the protein, including the PMIDs of
associated publications, cancer type, expression change
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Figure 1. Data content of dbDEPC. (A) Number of diﬀerentially expressed human proteins in each cancer. (B) Overlap between dbDEPC and two
external databases. (C) Statistics for genomic variations in human genes collected in dbDEPC. For all inclusive representation, circle surface areas in
B and C are disproportional so that small numbers can also be shown in the graph.
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If available, validation information (LTP, CGDCP,
CGC) also is provided in the expression section. The
annotation section contains diverse annotations: SNPs,
genomic structure variations, domain organization, Gene
Ontology, KEGG pathways and protein sequence. Taking
TFRC (IPI00022462.2) as an example (shown in
Supplementary Figure S1), the summary section brieﬂy
describes that TFRC is down-regulated in HCC; the
expression section shows that its fold change is 0.236766
or 0.3056256 based on an LTQ-FT MS experiment from
an paper with the PMID 1864787, its gene is reported as a
cancer-related gene based on the CGDCP database and it
has somatic mutations in non-Hodgkin’s lymphoma based
on the CGC database; and the annotation section notes 15
SNPs, copy number variations and inversion in the gene
region, and provides other functional terms.
Finally, dbDEPC’s proﬁle page can assist users to inves-
tigate diﬀerences in protein proﬁle among diﬀerent
cancers. If users input a protein list and select cancers of
interest on the proﬁle page (Figure 3A) the database will
return a heatmap visualizing the expression change of
proteins in multiple cancers (Figure 3B) and a table
listing all diﬀerentially expressed proteins. Up- and
down-regulation are represented by red and green color,
respectively. The color grade is dependent on a ‘validation
rank’, which is calculated based on number of data
sources (MS, LTP, CGDCP, CGC). Deeper color
denotes more sources that relate the protein with a partic-
ular cancer.
DATABASE AVAILABILITY
All data in dbDEPC are freely available for download
without password protection for academic users.
dbDEPC can be accessed via http://dbdepc.biosino
.org/index/, and data can be downloaded through the
download page as text ﬁles.
DISCUSSION AND CONCLUSION
Diﬀerentially expressed proteins in cancers are often
regarded as candidate biomarkers for diagnosis, prognosis
and prediction of response to therapy. Data in dbDEPC
(Figure 3C) show that some proteins have diﬀerential
Figure 2. The web interface of dbDEPC. (A) Search page. Proteins can be searched by IPI ID, Entrez gene ID, protein description or sequence.
(B) Browse page. Users can browse proteins in multiple selected cancers. (C) Result page for search or browse function. Results summarize protein
matches and provide a list of basic protein information. (D) A part of an example protein record. The whole protein page can be found in
Supplementary Figure S1, consisting of summary, expression, and annotation sections.
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while other proteins have diﬀerential expression in
multiple cancers (common proteins). For example, the
HSPA5 protein (78kDa glucose-regulated protein,
IPI00003362.2) is up-regulated in seven cancers, down-
regulated in two cancers and shows conﬂicting experimen-
tal results in another cancer. Speciﬁc proteins may be
candidate diagnostic biomarkers for speciﬁc cancers,
whereas common proteins could be regarded as
biomarkers for a group of cancers. dbDEPC increases
the reliability of information on cancer biomarkers by
curating proteomics data from multiple experiments. In
addition, dbDEPC is the ﬁrst database to emphasize
protein-level expression change in cancers based on
high-throughput MSy experiments.
In dbDEPC, the integration of data from multiple
cancers also allows for comparison among cancers based
on protein expression patterns. Using the expression
proﬁles of 1487 human proteins in 13 cancers (disregard-
ing two cancers with <50 diﬀerentially expressed proteins),
we obtained a hierarchical clustering by Jaccard similarity
coeﬃcient (Figure 3D). The associations among some
cancers might suggest underlying functional interaction.
For example, breast cancer clusters with ovarian cancer
and prostate cancer. This may imply that sex-hormone-
related cancers share some common biomarkers. Data
resources such as dbDEPC may facilitate development
of a more systemic understanding of the relationships
among diﬀerent cancers at the protein expression level.
Moreover, each protein in dbDEPC is annotated with
any known variations in its gene, allowing for exploration
of possible underlying mechanism for protein expression
changes in cancer. In fact, 99% of the genes collected in
dbDEPC have known SNPs and 41% have known
Figure 3. (A) Proﬁle page. Users can input a protein list and select cancers of interest to produce an expression heatmap. (B) Example heatmap of
diﬀerentially expressed proteins in multiple cancers. (C) Number of proteins in multiple cancers. (D) Clustering of cancers based on diﬀerentially
expressed protein proﬁles.
D662 Nucleic AcidsResearch, 2010, Vol.38,Database issuestructural variations in the human genome (including
copy number variations, inversions and insert-deletions).
Additionally, most diﬀerentially expressed genes in
dbDEPC are newly identiﬁed, with only 11% of genes
overlapping with two external databases. In conclusion,
dbDEPC is aimed to become an important reference
database for diﬀerentially expressed proteins in human
cancers. This new resource may facilitate cancer research
and contribute to biomarker discovery.
FUTURE DEVELOPMENT
With more and more cancer proteomics experiments
being performed, we plan to update dbDEPC annually.
The current dbDEPC collects primarily human proteins.
Model organisms are much easier to study and disease
models have contributed signiﬁcantly to cancer research
(24). Thus, we also plan to add data from mouse and
rat. Previously we have established a cancer-related gene
expression signature database (under submission).
Another important extension in the future will be to
explore the association between RNA levels as recorded
in the previous database and protein levels in the present
database.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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